GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioceltix SA (WAR:BCX) » Definitions » Total Receivables

Bioceltix (WAR:BCX) Total Receivables : zł0.13 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bioceltix Total Receivables?

Bioceltix's Total Receivables for the quarter that ended in Sep. 2024 was zł0.13 Mil.


Bioceltix Total Receivables Historical Data

The historical data trend for Bioceltix's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioceltix Total Receivables Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
0.59 0.07 0.46 0.03 0.17

Bioceltix Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.17 0.25 0.48 0.13

Bioceltix Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Bioceltix Total Receivables Related Terms

Thank you for viewing the detailed overview of Bioceltix's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioceltix Business Description

Traded in Other Exchanges
Address
Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.